HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 14, 2023-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the Board of Directors appointed Arnout Ploos van Amstel as
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 13, 2023-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023 , and recent business highlights.
Benaroya Research Institute to further characterize role of IL-7R α in TSLP and IL-7 signaling pathways Agreement underscores Zura Bio’s commitment to advancing science in immune-mediated disorders HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 12, 2023-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 14, 2023-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the second quarter ended June 30, 2023 , and recent business highlights.
SAN DIEGO --(BUSINESS WIRE)--Jun. 23, 2023-- Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio” or the “Company”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced it will be added to the Russell 2000® and
Tibulizumab (ZB-106) was licensed from Eli Lilly and Company on April 26, 2023 Total cash and cash equivalents of approximately $120 million is expected to fund planned clinical and operating activities through 2026 SAN DIEGO --(BUSINESS WIRE)--Jun. 6, 2023-- Zura Bio Limited (Nasdaq: “ZURA”)
Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist In connection with the transaction, Zura Bio announces pricing of $80 million private placement financing SAN DIEGO --(BUSINESS WIRE)--Apr. 27, 2023-- Zura Bio Limited (Nasdaq: “ZURA”) (“Zura” or “Zura Bio”), a
SAN DIEGO --(BUSINESS WIRE)--Apr. 14, 2023-- Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D.
SAN DIEGO --(BUSINESS WIRE)--Mar. 27, 2023-- As previously announced on March 21, 2023 , Zura Bio Limited (“Zura”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the closing of its business combination with
Zura Bio Limited to trade on Nasdaq as a clinical-stage biotechnology company focused on immunology Business combination results in approximately $65 million in gross cash proceeds to support research and development initiatives and potential future acquisitions Combined company to trade on Nasdaq